Focus Area 3: Imaging for treatment assessment
Imaging has started to emerge as a potential biomarker of clinical treatment response. Pre-treatment characterization of tumor phenotypes allows for stratification of patients into different treatment regimes. Early assessment and prediction of treatment response allows for individualized re-optimization of therapy. We are performing a series of Phase I clinical trials utilizing advanced molecular imaging to determine early treatment response and pharmacodynamics of several novel drugs, particularly targeting angiogenesis.